Brief: Arca Biopharma Enters Into Amendment On Demand Sales Agreement With Jonestrading Institutional Services
July 14 (Reuters) - ARCA Biopharma Inc ABIO.O :
* ARCA BIOPHARMA - ENTERED INTO AMENDMENT NO. 8 TO CAPITAL
ON
DEMAND SALES AGREEMENT WITH JONESTRADING INSTITUTIONAL SERVICES
* ARCA BIOPHARMA - AMENDMENT INCREASED MAXIMUM OFFERING
VALUE OF
SHARES WHICH CO MAY ISSUE & SELL FROM TIME TO TIME TO $32.4
MILLION
* ARCA BIOPHARMA - BELIEVES CASH & CASH EQUIVALENTS WILL BE
SUFFICIENT TO FUND OPERATIONS THROUGH END OF Q3 2021
Source text (https://bit.ly/2OCrZpr)
Further company coverage: ABIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oruka Therapeutics
See all newsOruka falls after reporting mid-stage data for psoriasis drug
Brief: Oruka Therapeutics Announces Positive Week 28 Data For Orka-001 From The Ongoing Everlast-A Trial Showing Deepening Of Responses Without Additional Dosing
Brief: Oruka Therapeutics Appoints Todd Edwards As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Accendra Health, Celestica, Sionna Therapeutics
Oruka Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary